Andrew Jackson/LinkedIn
Jun 13, 2026, 14:48
Andrew Jackson: Personalized Approaches to Catheter-Related Thrombosis Prevention
Andrew Jackson, Owner of IVTEAM LTD, shared a post on LinkedIn:
“Catheter-related thrombosis prevention – full text.
‘The use of anticoagulant drugs (both prophylactic and therapeutic), antiplatelet therapy, and PICC use significantly lowered the risk of CRT.
The findings support personalized prevention strategies and underscore the need for a well-designed randomized controlled trial to validate these findings’ La Cava et al (2026).”
Stay updated with Hemostasis Today.
-
Jun 13, 2026, 15:39Ritu Verma: Recognizing Deep Vein Thrombosis Before Complications Arise
-
Jun 13, 2026, 15:09Akshat Jain: Does Mitapivat Translate to Clinical Benefit in SCD?
-
Jun 13, 2026, 14:58Olga Benítez Hidalgo: New Evidence on Marstacimab in Hemophilia Care
-
Jun 13, 2026, 14:52Sophie Georgin-Lavialle: First ERN-RITA Recommendations on USAID
-
Jun 13, 2026, 14:45Ghazaleh Bankefors: Reconnecting Across Borders and Decades at EHA 2026
-
Jun 13, 2026, 14:41Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis
-
Jun 13, 2026, 14:36Heghine Khachatryan: Pregnancy, Thrombosis, and Aspirin – Who Really Needs Prophylaxis?
-
Jun 13, 2026, 14:24Thomas Stauch: ITP Therapeutics Enter a New Era of Targeted Treatment
-
Jun 13, 2026, 14:07Long-Term Outcomes and Future Directions in Hemophilia Gene Therapy: Insights from EHA 2026